It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Pharmaceutical
Enobia developed the super-orphan drug Strensiq™ (asfotase alfa) for the treatment of Hypophosphatasia. Enobia was acquired by Alexion for $1.1 billion in 2022.
Location
Montreal, Canada
History
Acquired by Alexion Pharmaceuticals for $1.1 billion in 2022
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
